Keywords
How to Cite
Abstract
Akromegaliya — somatotropin (o‘sish gormoni, GH) ortiqcha ishlab chiqarilishi natijasida yuzaga keladigan surunkali endokrin kasallik bo‘lib, u skelet, mushak va yumshoq to‘qimalarda giperplaziya va gipertrofiya rivojlanishiga olib keladi. Ushbu maqolada akromegaliyaning patofiziologik mexanizmlari, GH ortiqchaligi bilan bog‘liq metabolik buzilishlar va klinik namoyon bo‘lishi tahlil qilinadi. Tadqiqotda somatotropin gormoni oshishi natijasida yuzaga keladigan kardiovaskulyar, muskuloskeletal va metabolik asoratlar ko‘rib chiqilgan. Maqola akromegaliyaning erta aniqlash, diagnostika va bemorlarni monitoring qilishning klinik ahamiyatini yoritadi hamda zamonaviy davolash strategiyalarini taklif qiladi.
References
1. Melmed S. Acromegaly. N Engl J Med. 2006;355:2558–2573.
2. Colao A., Ferone D., Marzullo P., Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004;25(1):102–152.
3. Katznelson L., Laws E.R., Melmed S., et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:3933–3951.
4. Melmed S., Casanueva F.F., Klibanski A., et al. Guidelines for acromegaly management: an update. Pituitary. 2009;12:1–12.
5. Giustina A., Chanson P., Bronstein M.D., et al. A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol. 2014;10:243–258.
This work is licensed under a Creative Commons Attribution 4.0 International License.
